Dr. Powell Discusses CPI-613 in Hematologic Malignancies
In Partnership With:
Bayard L. Powell, MD, from the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses a phase I study that explored the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.
Bayard L. Powell, MD, the Director-At-Large and a Professor in Hematology & Oncology at the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses a phase I study that explored the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.
The well-tolerated toxicities and activity of CPI-613 has prompted further research of the agent as a treatment for patients with myelodysplastic syndromes, Powell notes. Additionally, a second phase I trial will be initiated to explore CPI-613 plus high-dose cytarabine as a treatment for patients with acute myeloid leukemia.
High levels of activity were observed with CPI-613, which is unusual for patients with advanced relapsed or refractory hematologic malignancies, Powell points out. As a result, further investigation into this agent is intriguing.
